Objective To explore disagreements in multiple systematic reviews (SRs) assessing the
benefit-to-harm ratio of thrombolytic therapy in patients with intermediate-risk pulmonary …

Background The role of thrombolytic agents in the treatment of pulmonary thromboembolism
(PTE) remains a controversial issue. The objective of this study is to assess the efficacy and …

Background Catheter-directed thrombolysis (CDT) is one of the newest treatment options for
submassive pulmonary embolism (sPE). This study will compare the efficacy and safety of …

Background: Thrombolytic agents and anticoagulants are the two classes of medication
used in the treatment of acute pulmonary embolism (PE). There is continuous renewal and …

Background The optimal treatment strategy of patients with pulmonary embolism
(PE)(especially those with intermediate risk) continues to evolve and remains controversial …

Background: Systemic thrombolysis (ST) is the guideline-recommended treatment for high-
risk pulmonary embolism (PE), although catheter-directed thrombolysis (CDT) may provide a …

Importance Thrombolytic therapy may be beneficial in the treatment of some patients with
pulmonary embolism. To date, no analysis has had adequate statistical power to determine …

OBJECTIVE To evaluate the safety and efficacy of catheter-directed thrombolysis (CDT)
versus systemic thrombolysis (ST) in the treatment of pulmonary embolism (PE). METHODS …

Background: Thrombolysis, either systemic (ST) or catheter-directed (CDT), may reduce
mortality in patients with intermediate-high and high-risk pulmonary embolism (PE), but with …

BACKGROUND: Randomized trials and meta-analyses have reached conflicting
conclusions regarding the risk benefit ratio of thrombolytic therapy or anticoagulant therapy …